A Phase 2 interventional study of Dexmedetomidine, midazolam; fentanyl in Intubated and Mechanically Ventilated Pediatric Subjects, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 9 sites in 2 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2017-04-13.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to characterize the pharmacokinetic and pharmacodynamic profile of dexmedetomidine administered as an intravenous loading dose followed by a continuous intravenous infusion in pediatric subjects ages ≥2 through \<17 years old.
This is a phase II, open-label, multicenter, escalating dose study evaluating the pharmacokinetics and pharmacodynamics of dexmedetomidine in pediatric subjects. The study population consists of initially intubated and mechanically ventilated pediatric subjects, ages ≥2 through \<17 years old, that require sedation in an intensive care setting for a minimum of 6 hours. Subjects will be divided into two groups based on age: Group I will consist of subjects ages ≥2 through \<6 years old and Group II subjects age ≥6 through \<17 years old. Within each group there will be four escalating dosing levels. Both groups can enroll simultaneously; however within each group, the next dose level cannot begin to enroll until all subjects have completed the previous dose level and the Data Safety Monitoring Board (DSMB) has approved enrollment to the next level. The level of sedation will be assessed using the Ramsay Sedation Scale (RSS). Based on these scores, and clinical judgment, additional sedation with midazolam will be administered according to the label. Pain will be assessed using the Faces, Legs, Arms, Cry \& Consolability (FLACC) scale. Venous blood samples for pharmacokinetic analysis will be obtained at designated times. The pharmacodynamic and safety measures that will be monitored and the pharmacodynamic impact of dexmedetomidine on tracheal extubation will also be explored if subject is extubated within 24 hours.
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
First submitted before Hospira became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: subjects must fit into one of the following age ranges at screening:
If female, subject is non-lactating and is either:
Exclusion Criteria:
Pediatric subjects with neurological conditions that prohibit an evaluation of sedation
Hypotension based on repeat assessments prior to starting study drug:
Pre-existing bradycardia prior to starting study drug defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose level 1
Drug: Dexmedetomidine, midazolam; fentanyl
Dose level 2
Drug: Dexmedetomidine, midazolam; fentanyl
Dose level 3
Drug: Dexmedetomidine, midazolam; fentanyl
Dose level 4
Drug: Dexmedetomidine, midazolam; fentanyl
Drug pages: Dexmedetomidine · Midazolam · Fentanyl
Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t)
Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t) for Dexmedetomidine
Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Area Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞)
Area under the concentration-time curve from time zero to the time infinity (AUC0-∞) for Dexmedetomidine
Time frame: ≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.
Observed Peak Plasma Concentration
Observed peak plasma concentration (Cmax) for Dexmedetomidine
Time frame: ≤30 min prior to start of the loading dose (LD); 5 min before finishing the LD; 0.5,1,2&4 to 6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4&10 hrs after end of MI.
Terminal Elimination Half-life (t1/2)
Terminal elimination half-life (t1/2) for Dexmedetomidine
Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Plasma Concentration at Steady State (Css)
Plasma concentration at steady state (Css) for Dexmedetomidine
Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Volume of Steady State Distribution (Vss)
Volume of steady state distribution (Vss) for Dexmedetomidine
Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Clearance (CL)
Clearance (CL) for Dexmedetomidine
Time frame: ≤30 min prior to start of loading dose (LD); 5 min before finishing LD; 0.5,1,2 & 4-6 hrs after start of maintenance infusion (MI); 30 min prior to end of MI (within 24 hrs of start of MI); 10 min after end of MI and 0.5,1,2,4 & 10 hrs after end of MI.
Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score
RSS Score range from 1 to 6: 1. Patient is anxious and agitated or restless, or both. 2. Patient is cooperative, orientated and tranquil. 3. Patient responds to command only. 4. Patient exhibits brisk response to light glabellar (between the eyebrows) tap or loud auditory stimulus. 5. Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus. 6. Patient exhibits no response to stimulus.
Time frame: Prior to loading (Baseline), 5 and 10 min during the load, at start of maintenance infusion and every 15 min for 1 hour, hourly during the maintenance period, before and within 5 min after midazolam or fentanyl dose during the dexmedetomidine infusion.
Number of Subjects Who Received Rescue Medication for Sedation (Midazolam) and Analgesics (Fentanyl)
Number of subjects who received rescue medication for Sedation (Midazolam) and analgesics (Fentanyl) while intubated during Treatment Period
Time frame: During the treatment period (Approximately 24 hours)
| Milestone | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Started | 16 | 14 | 15 | 14 |
| Completed | 15 | 13 | 14 | 14 |
| Not completed | 1 | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: No longer meets entry criteria | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t) for Dexmedetomidine
| picograms*hr/mL | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) | 2681.332 ± 2353.3418 | 6460.576 ± 3766.4657 | 16992.540 ± 29927.3911 | 28531.864 ± 17496.3985 |
Area under the concentration-time curve from time zero to the time infinity (AUC0-∞) for Dexmedetomidine
| picograms*hr/mL | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Time Infinity (AUC0-∞) | 3153.518 ± 3343.3451 | 6673.163 ± 3781.2183 | 17300.539 ± 29935.7647 | 28970.541 ± 17936.8970 |
Observed peak plasma concentration (Cmax) for Dexmedetomidine
| picograms per milliliter | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Observed Peak Plasma Concentration | 480.437 ± 625.9946 | 847.691 ± 633.7352 | 3385.569 ± 7384.0699 | 3090.939 ± 1625.5241 |
Terminal elimination half-life (t1/2) for Dexmedetomidine
| hour | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2) | 1.546 ± 0.3401 | 1.743 ± 0.3018 | 2.045 ± 0.6582 | 2.145 ± 0.6763 |
Plasma concentration at steady state (Css) for Dexmedetomidine
| picograms per milliliter | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Plasma Concentration at Steady State (Css) | 402.026 ± 535.1718 | 539.848 ± 166.7423 | 1347.284 ± 1308.0988 | 2827.144 ± 1169.4226 |
Volume of steady state distribution (Vss) for Dexmedetomidine
| Litre | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Volume of Steady State Distribution (Vss) | 56.808 ± 44.5127 | 35.246 ± 25.0233 | 32.789 ± 22.5478 | 43.652 ± 30.6577 |
Clearance (CL) for Dexmedetomidine
| Litre/hour | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Clearance (CL) | 32.208 ± 40.3982 | 20.268 ± 10.3508 | 18.565 ± 8.6995 | 22.199 ± 14.1623 |
RSS Score range from 1 to 6: 1. Patient is anxious and agitated or restless, or both. 2. Patient is cooperative, orientated and tranquil. 3. Patient responds to command only. 4. Patient exhibits brisk response to light glabellar (between the eyebrows) tap or loud auditory stimulus. 5. Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus. 6. Patient exhibits no response to stimulus.
| units on a scale | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Level of Sedation Based on Average Ramsay Sedation Scale (RSS) Score | 2.4 ± 0.96 | 2.8 ± 0.74 | 2.4 ± 0.5 | 4.0 ± 1.04 |
Number of subjects who received rescue medication for Sedation (Midazolam) and analgesics (Fentanyl) while intubated during Treatment Period
| participants | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| Midazolam | 7 | 7 | 5 | 3 |
| Fentanyl | 12 | 10 | 13 | 8 |
Collected over From the start of study drug administration until 24 hours following discontinuation of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | — | 1/16 (6.3%) | 11/16 (68.8%) |
| Dose Level 2 | — | 0/14 (0%) | 12/14 (85.7%) |
| Dose Level 3 | — | 0/15 (0%) | 10/15 (66.7%) |
| Dose Level 4 | — | 0/14 (0%) | 13/14 (92.9%) |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 1/16 | 0/14 | 0/15 | 0/14 |
| Event | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/16 | 4/14 | 2/15 | 2/14 |
| PyrexiaGeneral disorders | 4/16 | 4/14 | 2/15 | 3/14 |
| HypokalaemiaMetabolism and nutrition disorders | 4/16 | 3/14 | 1/15 | 3/14 |
| SedationNervous system disorders | 0/16 | 0/14 | 0/15 | 3/14 |
| HypertensionVascular disorders | 2/16 | 2/14 | 3/15 | 3/14 |
| NauseaGastrointestinal disorders | 1/16 | 2/14 | 1/15 | 2/14 |
| PainGeneral disorders | 0/16 | 1/14 | 0/15 | 2/14 |
| Procedural painInjury, poisoning and procedural complications | 1/16 | 2/14 | 0/15 | 0/14 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/16 | 0/14 | 0/15 | 2/14 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/16 | 0/14 | 0/15 | 2/14 |
Safety Population: Participants who received any amount of study drug were included in the Safety Population
| Age, Continuous(years) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| Mean | 6.358 ± 3.4673 | 7.457 ± 4.5990 | 8.379 ± 4.4962 | 7.462 ± 4.2259 | 7.395 ± 4.1571 |
| Age, Customized(participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| ≥2 through <6 years | 8 | 6 | 6 | 6 | 26 |
| ≥6 through <17 years | 8 | 8 | 9 | 8 | 33 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| Female | 10 | 8 | 9 | 5 | 32 |
| Male | 6 | 6 | 6 | 9 | 27 |
| Race (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 2 | 6 |
| White | 12 | 12 | 13 | 10 | 47 |
| More than one race | 2 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 1 | 2 | 3 |
The record gives a start of Nov 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 5 years 4 months after primary completion. A results delay was requested in Sep 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Midazolam · Fentanyl
Hospira, now a wholly owned subsidiary of Pfizer →